Gastric Cancer | Clinical

Updated Results Support Efficacy of Trastuzumab Deruxtecan in Metastatic Gastric/GEJ Cancer

September 11, 2022

New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Doctors Debate: Is PD-L1 Testing Necessary Before Starting ICI Therapy in Gastroesophageal Cancer?

March 28, 2022

During a debate at the Gastrointestinal Cancers Symposium, Florian Lordick, MD, argued that knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. He was challenged by Aaron James Scott, MD, who argued that knowledge of PD-L1 is not necessary before initiating immune checkpoint inhibitor therapy.